

1 **“Learn from the lessons and don’t forget them”:**
2 **Identifying transferable lessons for COVID-19 from**
3 **meningitis A, yellow fever, and Ebola virus disease**
4 **vaccination campaigns**

5
6 Julie Collins¹, Rosie Westerveld², Kate A Nelson², Hana Rohan¹, Hilary Bower¹, Siobhan
7 Lazenby³, Gloria Ikilezi³, Rebecca Bartlein³, Daniel G Bausch¹, David S Kennedy¹

8
9 ¹UK Public Health Rapid Support Team, London School of Hygiene & Tropical
10 Medicine/Public Health England, London, United Kingdom

11 ²London School of Hygiene & Tropical Medicine, London, United Kingdom

12 ³Gates Ventures, Seattle, United States of America

13
14
15 **Corresponding author**

16 Julie Collins

17 UK Public Health Rapid Support Team, London School of Hygiene & Tropical
18 Medicine/Public Health England

19 Keppel Street, London WC1E 7HT, United Kingdom

20 Email: julie.collins@lshtm.ac.uk

21
22 **World count:** 5,217

23 **ABSTRACT**

24 **Introduction:** COVID-19 vaccines are now being distributed to low- and middle-income
25 countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have
26 significant experience implementing vaccination campaigns to respond to epidemic threats
27 but are often hindered by chronic health system challenges. We sought to identify
28 transferable lessons for COVID-19 vaccination from the rollout of three vaccines that
29 targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow
30 fever); and rVSV-ZEBOV (Ebola virus disease).

31 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Methods:** We conducted a rapid literature review and 24 semi-structured interviews with
33 technical experts who had direct implementation experience with the selected vaccines in
34 Africa and South America. We identified barriers, enablers, and key lessons from the
35 literature and from participants' experiences. Interview data were analysed thematically
36 according to seven implementation domains.

37

38 **Results:** Participants highlighted multiple components of vaccination campaigns that are
39 instrumental for achieving high coverage. Community engagement is an essential and
40 effective tool, requiring dedicated time, funding and workforce. Involving local health
41 workers is a key enabler, as is collaborating with community leaders to map social groups
42 and tailor vaccination strategies to their needs. Vaccination team recruitment and training
43 strategies need to be enhanced to support vaccination campaigns. Although recognised as
44 challenging, integrating vaccination campaigns with other routine health services can be
45 highly beneficial if well planned and coordinated across health programmes and with
46 communities.

47

48 **Conclusion:** As supplies of COVID-19 vaccines become available to LMICs, countries need
49 to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups, and
50 respond to potential community concerns. Lessons from the implementation of these three
51 vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and
52 other epidemic vaccination campaigns.

53

54

KEY QUESTIONS

What is already known?

- Low- and middle-income countries (LMICs) have substantial experience conducting vaccination campaigns as a part of epidemic responses.
- Vaccination campaigns in LMICs are impacted by a number of systemic challenges, including poor infrastructure, limited resources, and an overstretched health workforce.
- Meningitis A, yellow fever and Ebola virus disease vaccines have been recently rolled out in LMICs to respond to epidemic threats. These campaigns share some of the same challenges anticipated for COVID-19 vaccination, including the focus on adult target groups.

What are the new findings?

- Extensive community engagement is crucial when targeting adults for vaccination in LMICs to shift community perceptions that vaccination is only associated with children.
- Working with community leaders to map social groups and plan effective vaccination strategies is vital to achieving high vaccination coverage.
- Recruiting local health workers who have established links to the community, can speak the local language, and can leverage existing rapport to increase vaccination uptake, is preferred over bringing in staff from other regions.
- Vaccination training quality is reduced as information is transmitted down to lower levels using the ‘cascade’ or ‘training-of-trainers’ model. Training for vaccination campaigns in LMICs has been further affected by COVID-19 and the move to remote learning. Where access to training is limited, a greater emphasis is placed on resource-intensive supervision to ensure the effectiveness of vaccination campaigns.

What do the new findings imply?

- Previous vaccination campaigns conducted during epidemics are an important source of transferable lessons that can assist countries in their COVID-19 vaccine rollouts and future epidemic preparedness.
- Our findings suggest that countries can strengthen vaccination campaigns during epidemics by recruiting local health workers to assist vaccination teams, by providing operational funding for pre-campaign community engagement and social mobilisation activities, and by examining the effectiveness of vaccination training and developing new models where needed.
- Implementing these lessons for COVID-19, however, relies on countries having sufficient vaccine supply.

55

56

57 INTRODUCTION

58 Development and mass-production of multiple safe and effective COVID-19 vaccines have
59 progressed faster than expected. There are signs that, with high population-level vaccination
60 coverage, pre-pandemic levels of mobility and economic activity could safely resume.[1, 2]
61 However, COVID-19 vaccination has been dominated by high-income countries, which have
62 purchased 51% of vaccine doses yet represent only 14% of the global population.[3] As of 10
63 July 2021, only 1% of people in low-income countries had received at least one dose of a
64 COVID-19 vaccine.[4] Adequate vaccine supply is a critical first step. Access mechanisms,
65 such as the COVID-19 Vaccines Global Access (COVAX) initiative, have been established
66 to support vaccine supply in low- and middle-income countries (LMICs); however, modest
67 initial targets have not been met.[5] In addition to increasing access to vaccine supplies,
68 critical work is needed to ensure that vaccines reach their intended target groups.

69
70 Many factors can complicate vaccine rollouts in LMICs, including limited health and
71 surveillance infrastructure, insufficient cold chain transportation and storage capacity, and an
72 under-resourced health workforce.[6, 7] However, some LMICs also have substantial
73 experience in conducting vaccination campaigns to prevent or respond to epidemics, from
74 which valuable lessons can be drawn for the rollout of COVID-19 vaccines.

75
76 We examined vaccination campaigns recently conducted as part of epidemic responses
77 (hereafter, ‘vaccination campaigns’) in LMICs in Africa and South America. We selected
78 three vaccines – MenAfriVac (meningitis A), 17D (yellow fever), and rVSV-ZEBOV (Ebola
79 virus disease) – that share some of the same challenges anticipated for COVID-19 in LMICs
80 (Table 1) to capture insights and make recommendations for countries implementing
81 COVID-19 vaccination campaigns.

82 **TABLE 1: Characteristics of the selected vaccines**

Criteria	Ebola virus disease (rVSV-ZEBOV)	Yellow Fever (17D)	Meningitis A (MenAfriVac)
Cold chain requirements	-70°C	2-8°C [61]	2-8°C[62]
Dose regimen	Single Dose	Single Dose	Single Dose[63]
Target populations during outbreak-related campaigns	Adults aged ≥18 years.* Healthcare workers, contacts of confirmed cases & contacts of contacts.	Children and adults† aged ≥9 months[61]	Children and adults aged 1 – 29 years[63]
Regions	Democratic Republic of Congo, Burundi, Guinea, Liberia, Sierra Leone, Rwanda, Uganda	Africa and South America	"Meningitis belt" in Africa – sub-Saharan Africa from Senegal to Ethiopia [62]
Year developed/licenced	2019[64]	1927[61]	2010[62]
Key similarities with COVID-19 Vaccines	Primarily targeted adults; required ultra-cold chain management	Targeted adults as well as children	Targeted adults as well as children

83 *Children aged 6–17 years also included in some Phase 1 to 3 trials[65]; Children >6 months were included in
84 the 2018–2020 outbreak in Democratic Republic of Congo under compassionate use protocol.[66]

85 †Upper limit age group varied by outbreak.

86

87 **METHODS**

88 We conducted a rapid literature review followed by semi-structured interviews with technical
89 experts to identify barriers, enablers, and lessons from implementing the three vaccines in
90 recent outbreaks in Africa and South America.

91

92 We designed a thematic framework of seven domains (Table 2) to guide the research, based
93 on existing vaccine readiness assessment tools and gap analyses developed for implementing
94 Ebola virus disease (EVD) vaccines[8, 9] and COVID-19 vaccination guidelines developed
95 by the World Health Organization (WHO).[10]

96

97

98 **TABLE 2: Thematic framework for the implementation of vaccines**

Domain	Description
1) Planning and coordination	Macro/microplanning; funding; vaccination campaign management; decision-making; coordination and communication mechanisms; stakeholder engagement; stakeholder roles; policy and regulatory framework.
2) Target groups and delivery strategies	Target group inclusion and exclusion criteria; prioritisation of groups; communication of target groups; delivery strategies for vaccination (e.g., house-to-house, fixed post, mobile fixed post); tailoring of delivery strategies to reach sub-groups.
3) Logistics and supply	Supply chain; infrastructure; vaccine storage; cold chain (and ultra-cold chain) management; transportation; equipment (including personal protective equipment); waste disposal.
4) Vaccination teams	Team composition and roles; recruitment; training techniques and processes; team coordination and communication.
5) Vaccination monitoring and safety surveillance	Identifying cases of disease and differentiating between similar pathogens; recording, reporting and monitoring vaccination coverage; identification, reporting and management of adverse events following immunisation; use of technology.
6) Community engagement and social mobilisation ¹	Developing relationships with communities and working together to conduct vaccination activities; strategies to increase vaccine demand and uptake, including communication strategies.
7) Vaccine confidence ²	Perceptions and attitudes toward the vaccine; factors contributing to confidence or resistance; types of rumours and misinformation; strategies to address rumours and misinformation.

99 ¹World Health Organization definitions of community engagement and social mobilisation were used in this
 100 research, however it was noted that these terms were often used interchangeably by key informants.[67, 68]

101 ²Vaccine confidence was not identified in articles retrieved in the literature review but was discussed in the key
 102 informant interviews.

103

104

105 **Literature review**

106 We searched Embase, MEDLINE & Global Health databases in early February 2021.
107 Searches were not restricted by location, year of publication or language. Search terms are
108 provided in Appendix 1. For inclusion, articles were required to 1) focus on an LMIC in
109 Africa or South America, and 2) describe the implementation of one of the selected vaccines.
110 Following de-duplication, we conducted title and abstract screening, followed by full-text
111 screening. Texts meeting these criteria were cross-referenced to identify additional relevant
112 papers for inclusion. Data were extracted from the included articles according to the thematic
113 framework (Table 2).

114

115 **Key informant interviews**

116 *Participants*

117 Using a purposive sampling approach, we identified technical experts through the
118 professional networks of the research team and via "snowball sampling." Participants had
119 either 1) involvement in the rollout of one or more of the selected vaccines through global
120 initiatives or organisations, or 2) implementation experience with one or more of the selected
121 vaccines at either a regional, national, or sub-national level.

122

123 *Data collection*

124 We developed a semi-structured interview guide, based on preliminary findings from the
125 literature review and using the thematic framework (Table 2). The interview guide helped
126 elicit specific information across the domains but was sufficiently flexible to allow the
127 interview to be guided by the participants' experiences. While the interviews focused on the
128 three selected vaccines, interviewers did not dissuade participants from drawing on their

129 experiences from other campaigns. Participants were given the opportunity to reflect on their
130 experiences with the initial COVID-19 vaccination rollout, where appropriate.

131

132 Interviews were conducted virtually via Zoom and were in either English or French.

133 Interviews were digitally recorded, professionally translated to English when required, and

134 transcribed. The interviewers verified each transcript to ensure accuracy before commencing

135 data analysis.

136

137 *Data analysis*

138 We analysed the qualitative data thematically, using deductive and inductive coding in Nvivo

139 12 Plus. A coding framework was developed based on the seven domains in the thematic

140 framework (Table 2), along with additional themes emerging from the data. Key trends,

141 barriers, enablers, and lessons shared by participants were identified across each theme.

142

143 **RESULTS**

144 **Literature review**

145 Thirty-seven studies met the inclusion criteria (Figure 1): 15 meningitis A[11-25]; 11 Ebola

146 virus disease[26-36]; eight yellow fever[37-44]; one meningitis A and yellow fever[45]; and

147 two focusing on general vaccination strategies.[46, 47] Twenty-eight studies focused on

148 African countries[11-35, 40, 44, 46, 47]; two on South American countries[41, 43]; and six

149 studies did not specify a region[36-39, 42, 45] (Table 3).

150

151

152 **TABLE 3: Studies identified through the literature review**

Author	Year	Disease				Location		
		Meningitis A	Ebola	Yellow fever	General	Africa	South America	Global
<i>Aguado, M.T., et al.[11]</i>	2015	X				X		
<i>Burchett, H.E.D., et al.[12]</i>	2014	X				X		
<i>Marchetti, E., et al.[13]</i>	2012	X				X		
<i>Zipursky, S., et al.[14]</i>	2014	X				X		
<i>Djingarey, M.H., et al.[15]</i>	2012	X				X		
<i>Cibrelus, L., et al.[16]</i>	2015	X				X		
<i>Okwo-Bele, J.M. et al.[17]</i>	2011	X				X		
<i>Tartof, S., et al.[18]</i>	2013	X				X		
<i>Mbaeyi, S., et al.[19]</i>	2020	X				X		
<i>Daugla, D.M., et al.[20]</i>	2014	X				X		
<i>Nkwenkeu, S.F., et al.[21]</i>	2020	X				X		
<i>Patel, J.C., et al.[22]</i>	2019	X				X		
<i>Diomande, F.V.K., et al.[23]</i>	2015	X				X		
<i>Berlier, M., et al.[24]</i>	2015	X				X		
<i>Djingarey et al.[25]</i>	2015	X				X		
<i>Ughasoro, M.D., et al.[26]</i>	2015		X			X		
<i>Wolf, J., et al.[27]</i>	2020		X			X		
<i>Jusu, M.O., et al.[28]</i>	2018		X			X		
<i>Samai, M., et al.[29]</i>	2018		X			X		
<i>Dean, N.E., et al.[30]</i>	2019		X			X		
<i>Hossmann, S., et al.[31]</i>	2019		X			X		
<i>Grantz, K.H., et al.[32]</i>	2019		X			X		
<i>Juan-Giner, A., et al.[33]</i>	2019		X			X		
<i>Elemuwa, C., et al.[34]</i>	2015		X			X		
<i>Alenichev, A. et al.[35]</i>	2020		X			X		
<i>Folayan, M.O., et al.[36]</i>	2016		X					X
<i>Tomashek, K., et al.[37]</i>	2019			X				X
<i>Chen, L.H. et al.[38]</i>	2017			X				X
<i>Vannice, K. et al.[39]</i>	2018			X				X
<i>Barrett, A.D.T. et al.[40]</i>	2016			X		X		
<i>Possas, C., et al.[41]</i>	2018			X			X	
<i>Martins, R.M., et al.[42]</i>	2013			X				X
<i>Flamand, C., et al.[43]</i>	2019			X			X	
<i>Legesse, M., et al.[44]</i>	2018			X		X		
<i>Nguyen, T. et al.[45]</i>	2019	X		X				X
<i>Yakum, M.N., et al.[46]</i>	2015				X	X		
<i>Sow, C., et al.[47]</i>	2018				X	X		

153

154 **Key informant interviews**

155 Twenty-four key informants were interviewed from late February to late April
156 2021. Participants included health professionals and technical officers working for national
157 health agencies, multilateral organisations (including United Nations agencies), non-
158 governmental organisations (NGOs), and academia. All participants had worked with at least
159 one of the selected vaccines in LMICs, with 23 reflecting on their vaccination campaign
160 experiences across West, Central and East Africa, and one on their experiences in South
161 America. Sixty-three per cent of participants were male (15/24). The average interview length
162 was one hour (range 40–80 minutes).

163

164 **Key lessons for COVID-19 vaccination**

165 We present findings from the literature review and qualitative interviews together, according
166 to the thematic framework. Illustrative quotes have been included along with the participant's
167 organisation type and regions where they worked with the selected vaccines.

168 **1) Planning and coordination**

169 *Early engagement with diverse stakeholders to support campaign planning*

170 Successful vaccination campaigns engage early with a broad network of stakeholders to
171 support detailed pre-campaign planning. Collaboration with other government departments
172 (e.g., Ministries of Education, Finance, and Transport) was considered crucial by interview
173 participants, since health teams often relied on their support to conduct activities. Involving
174 staff at the health facility level was critical to understand context, geography and social
175 nuances within their catchment area.

176 For the success of the campaign, we must have a strong microplan, originating from
177 the health facility itself that is going to be involved. ... [without this] you may still

178 succeed in the vaccination coverage, but you will have a lot of hurdles. (National
179 health agency, East Africa)

180 While participants noted the time pressures of reactive vaccination campaigns, the
181 importance of engaging and planning with health facility staff and communities before
182 commencing vaccination was consistently emphasised.

183
184 International partners, such as multilateral organisations, NGOs, and civil society
185 organisations, play a key role in supporting campaign resourcing and implementation.
186 Disease-specific initiatives, such as the Meningitis Vaccine Project and the Eliminate Yellow
187 Fever Epidemics strategy, have assisted with access to vaccines, supported vaccine
188 implementation and promoted mutual learning between countries.[13] However, participants
189 did raise concerns about the sustainability of mass vaccination activities without such
190 external support.[23-25]

191
192 COVAX and other initiatives are working to improve access to COVID-19 vaccines for
193 LMICs. Still, some participants called attention to a gap in operational funding needed to
194 support vaccination activities, such as community engagement.

195 As long as the funds for operations are available, then it will be much easier for us to
196 roll out any vaccine activity. ... Fine, you are giving us the vaccine free of charge, but
197 you should also factor in the operational costs. (Multilateral organisation, East Africa)

198
199 Insufficient operational funding has impaired some countries' capacity to conduct preparatory
200 activities for COVID-19 vaccination campaigns, such as raising awareness and encouraging
201 vaccine uptake among health workers; participants were apprehensive about vaccine uptake
202 in the absence of such activities.

203

204 *Establishing strong coordination mechanisms*

205 Robust coordination mechanisms are necessary to provide direction and oversight over
206 campaign activities. Participants highlighted the benefits of an incident management system
207 (IMS) that delineates the roles and responsibilities of government departments (e.g., disease
208 control, routine immunisation, national drug authorities) and partner organisations and
209 prevents the duplication of response efforts.

210 [The IMS] helped us to coordinate the partners, because at the beginning of Ebola in
211 West Africa, everybody took the money, went into the community without asking the
212 others. [It was a] nightmare, until we found this coordination mechanism, this
213 harmonisation of all the priorities in one single strategic response plan. (Multilateral
214 organisation, West and Central Africa)

215 Within the IMS, technical working groups (e.g., logistics, social mobilisation) can foster
216 collaboration between health agencies and international partners. In relation to COVID-19,
217 some participants outlined how they were drawing on the strength of previously established
218 technical working groups to conduct rapid vaccination preparations. The need for effective
219 communication both within and between working groups was emphasised during interviews.
220 Regarding EVD vaccination campaigns, some participants highlighted how the ‘industry’ of
221 the outbreak led to competition and fragmentation. Different response teams (e.g., contact
222 tracing and vaccination teams) vied to demonstrate their unique contributions and retain high-
223 paying positions.[32]

224 **2) Target groups and delivery strategies**

225 *Target groups and community perceptions*

226 Vaccinating adults requires a shift in community understandings of vaccination, which are
227 traditionally associated with children. Perceptions and suspicions around adult target groups
228 need to be recognised and accounted for in vaccination planning. Participants highlighted

229 how communities might have concerns around both being included and excluded from
230 vaccination target groups. For example, the inclusion of adults of reproductive age was
231 frequently associated with concerns that vaccines affected fertility. On the other hand, some
232 participants noted concerns from pregnant women about being initially excluded from
233 receiving the rVSV-ZEBOV vaccine. Younger adults, notably young males, were described
234 in both the literature and interviews as often being indifferent to meningitis A or yellow fever
235 vaccination; their perceived risk of contracting the disease or developing severe outcomes
236 was low so they did not see the benefit of being vaccinated. Interview participants also
237 outlined how older adults sometimes needed convincing that it was worthwhile to vaccinate
238 them in their stage of life.

239 "No, no, no, at my age," some will tell you, "at my age I think I'm just about due, [to
240 die]." ... [We use] persuasions in line with trying to make them valuable to society.
241 (National health agency and academia, East Africa)

242 Participants spoke of spending considerable time explaining the disease and the vaccine
243 development, safety, and regulatory processes to communities, along with why adults were
244 being targeted for vaccination. This type of meaningful engagement with communities is
245 critical to facilitate a better understanding of the disease and address community concerns
246 around vaccination target groups. However, participants noted that time and resources (e.g.,
247 staff, development of messages, training, transport, and per diems) are required for this
248 process.

249

250 *Tailoring delivery strategies*

251 Tailored delivery strategies are required for groups that experience either physical or social
252 barriers to accessing vaccination. For example, young adult males were sometimes unable to
253 access vaccination sites due to work commitments during meningitis A campaigns. To

254 improve uptake, vaccination centres were positioned near facilities they frequented, such as
255 workplaces, hotels, restaurants, and transport hubs.[25] Social and cultural norms were also
256 identified as potential barriers to vaccination. During meningitis A campaigns in West Africa,
257 sociocultural beliefs sometimes prevented men from attending vaccination centres at the
258 same time as women and children.[25] Similarly, one participant (Multilateral organisation,
259 East and West Africa) described how young married women might not be able to attend a
260 public vaccination site without authorisation from their spouses. Engaging with community
261 leaders to map social groups and identify when, where, and how vaccination teams can most
262 effectively reach sub-groups is vital to achieving high vaccination coverage.

263

264 *Integrating vaccination campaigns with other health services*

265 Participants highlighted how accessing remote locations during vaccination campaigns can be
266 viewed as an important opportunity to provide other health services. Integrating multiple
267 vaccination campaigns can minimise time burdens on both communities and health workers
268 and can potentially increase uptake by offering additional health services that the community
269 prioritises. For example, one participant (National health agency, West Africa) described how
270 vaccination uptake in nomadic communities increased following the development of a
271 collaborative human-animal health initiative where vaccinations and health assessments for
272 community members and their livestock were conducted during the same visit. While some
273 participants viewed multi-service integration positively, they also mentioned challenges
274 around the coordination and reporting of multiple activities.

275

276 Integrating COVID-19 vaccination with other services requires careful planning with
277 communities to prevent potential spillover of COVID-19 vaccine hesitancy to other services.

278 In some settings, participants had already observed an adverse effect on the uptake of other
279 vaccines due to COVID-19.

280 Some [community members] are really against COVID-19 vaccination, they say “no,
281 you want to smuggle in the COVID-19 vaccine in the name of yellow fever.” (National
282 health agency, West Africa)

283 Consequently, participants outlined how vaccination teams have had to differentiate between
284 vaccines for COVID-19 and vaccines for other pathogens, reassuring communities that the
285 dispensed vaccine was *not* a COVID-19 vaccine. This differentiation was seen to be the only
286 way to ensure that the uptake of other vaccines was not compromised, but it adds to the
287 complexity of messaging for COVID-19 vaccines.

288 **3) Logistics and supply**

289 *Vaccine storage and transportation*

290 Participants outlined how vaccine storage assessments were necessary before each campaign
291 and stressed how quickly capacity could change at the facility level, affecting product
292 viability. During meningitis A clinical trials, mock-up shipments of MenAfriVac were sent to
293 each country to test the supply chain and ensure the vaccines had been correctly handled
294 throughout their journey.[13] In-depth logistical planning exercises and simulations can help
295 identify and mitigate potential areas of vaccine wastage.[12, 48]

296
297 Subnational vaccine storage hubs that enable the rapid movement of supplies during a
298 campaign are critical to success, particularly in areas where it is difficult to estimate the target
299 population. Some vaccines (i.e., rVSV-ZEBOV, mRNA vaccines for COVID-19) require
300 ultra-cold chain (UCC) infrastructure. While centralised depots with reliable access to
301 electricity may seem most effective, some participants felt that centralisation led to

302 unacceptable delays. Increasing storage capacity and cold chain management at the
303 subnational level was seen as a solution to ensure the timely distribution of vaccines during a
304 campaign.

305
306 During EVD vaccine clinical trials, significant investments were made to ensure appropriate
307 UCC infrastructure was in place.[28] Interview participants believed that UCC was generally
308 well managed during EVD outbreaks. However, they also emphasised that qualified staff
309 (e.g., pharmacists, consultants) were employed to manage this process during well-resourced
310 campaigns. Multi-dose vaccine vials simplified UCC storage and transport, requiring less
311 space than single-dose vials, but one participant (NGO, Central Africa) noted how concerns
312 around vaccine wastage with multi-dose vials affected how vaccination teams interacted with
313 those waiting to be vaccinated. In some instances, vaccination teams would wait for sufficient
314 eligible persons to arrive before opening the vial to limit the risk of vaccine wastage. This
315 approach assumed that community members could wait, sometimes for hours, to receive their
316 vaccination.

317 [Vaccination teams] wouldn't open a vial until [enough] people were there ...
318 [community members] would arrive at 8 am and they would still be there at 4 pm,
319 waiting for the other people to turn up. And if [the vaccination team] didn't get
320 [enough] people they wouldn't open the vial and they would go away again. (NGO,
321 Central Africa)

322 **4) Vaccination teams**

323 *Recruiting, training, and resourcing vaccination teams*

324 Participants consistently referred to the importance of recruiting local health workers who
325 have established links to the community, can speak the local language, and can leverage
326 existing rapport to increase uptake, rather than bringing in staff from other regions.

327 If we need healthcare people, we try to take the village nurses themselves, we train
328 them in the activity, and they go to meet the community. ... So training the local
329 community is very good, not finding the people in the capital and sending them to the
330 village. (Multilateral organisation, West and Central Africa)

331 However, local recruitment depends on the availability of skilled workers and may place
332 additional workload on already overburdened staff. Seconding staff to vaccination activities
333 can also adversely affect the quality and availability of routine health services. Participants
334 referred to how the outbreak response ‘industry’ during EVD outbreaks drained the local
335 health workforce, with staff leaving routine posts to gain higher salaries in the response.

336
337 Recruiting new graduates and recently retired health staff to support large-scale vaccination
338 campaigns was a strategy identified in both the literature and interviews.[29] However,
339 participants were wary of introducing a parallel system that potentially excludes existing,
340 trusted frontline health workers from vaccination campaigns. Some participants also
341 highlighted lengthy recruitment processes as a barrier to bringing on additional staff.

342
343 Provision of training for vaccination teams is an essential component of pre-campaign
344 activities,[12] but participants highlighted issues around training quality at the lower levels of
345 the frequently used ‘cascade’ or ‘training-of-trainers’ model. Training deficiencies are often
346 picked up and corrected in the field through supervision, participants outlined, but this is
347 resource intensive. The transition to remote training to comply with COVID-19 physical
348 distancing guidelines has introduced additional barriers to training delivery; many settings
349 have limited access to hardware and stable internet. Participants also raised concerns
350 regarding the quality of training on practical skills through virtual methods.

351 Most people couldn't access the internet and use a virtual platform. ... And when you
352 evaluate the performance [of the training], it is very low, because most people
353 couldn't attend it. (National health agency, East Africa)

354 Even when in-person training has been possible, physical distancing measures have reduced
355 the capacity of commonly used training facilities, thereby restricting the number of people
356 able to take part.

357

358 Inadequate resourcing of vaccination teams and lengthy processes for distributing funding
359 were identified as additional barriers, with participants stating that it was unfair to expect
360 teams to perform without funding.

361 [The resources] must be available, and that is very key, available and handed to the
362 people that actually get involved, because if you are going to keep the team in the
363 field for the whole day and they don't have support or any money to get themselves a
364 drink or something to eat, it is going to have a negative effect. (National health
365 agency, East Africa)

366 **5) Vaccination monitoring and safety surveillance**

367 *Locally led, integrated vaccination monitoring*

368 The ability to link a person to their vaccination, any subsequent adverse events following
369 immunisation, and any breakthrough infections is an important aspect of vaccination
370 campaign monitoring and can increase community confidence by providing organised,
371 accurate information on the progress of the campaign. However, outside of clinical trials,
372 most interview participants described complex data aggregation processes where indicators
373 held in different datasets were collated and compared. Innovations in electronic case-based
374 surveillance systems, such as the use of QR codes and new modules to track immunisation
375 status and adverse events following immunisation, were mentioned by a small number of

376 participants in relation to COVID-19. Nevertheless, most of these systems still involved a
377 combination of entering data on paper in the field and subsequently inputting the data to
378 electronic systems at higher levels (i.e., district level). Parallel systems and limited
379 standardisation in data collection can severely hamper the analysis and operational use of
380 vaccination coverage, vaccine efficacy, and vaccine safety data.[27]

381

382 Participants highlighted how limited access to data held by different organisations negatively
383 affected response efforts. In one example, a participant (NGO, Central Africa) reported that
384 government health staff could not compare newly confirmed EVD cases against the records
385 of those who had been vaccinated due to a lack of access to crucial datasets held by other
386 organisations. Participants described tensions when governments were not sufficiently
387 supported in the ownership, storage, access, and analysis of vaccination data, highlighting the
388 importance of these elements for the success of campaigns.

389 **6) Community engagement and social mobilisation**

390 *Timing and approach of community engagement*

391 Community engagement and social mobilisation are vital components of a successful
392 vaccination campaign. Participants repeatedly raised the importance of having a clear strategy
393 for engaging with communities, with consistent messaging around the disease, the vaccine,
394 vaccination target groups, and adverse events following immunisation. Some participants
395 linked the success of meningitis A vaccination to the Meningitis Vaccine Project's detailed
396 communication plan, which was developed, implemented and refined over a few years.
397 Importantly, participants outlined, the objective of the Meningitis Vaccine Project's
398 communication plan was to build community awareness and expectation for the vaccine well
399 in advance of the campaigns.

400 The population was very aware [of meningitis], they were really waiting for this
401 vaccine. When we did the [meningitis A] vaccination campaign ... the vaccination
402 centres opened at 8 am, but at 5 am people were already queuing to get the vaccine.
403 (Multilateral organisation, West, Central and East Africa)

404 While participants recognised that reactive vaccination campaigns face intense time
405 pressures, they insisted that community engagement should precede vaccination campaigns
406 by a minimum of one to two months. This lead-in time is necessary to develop relationships
407 with community members, respond to vaccination queries, and tailor delivery strategies.

408
409 Participants stressed that early vaccine acceptance could not be taken as indicative of
410 community sentiment throughout a campaign. Continuous engagement with communities was
411 considered crucial to monitoring community acceptance, responding to concerns around
412 vaccine safety, and explaining the rationale behind target group selection. Reconnecting with
413 communities and providing feedback at the end of the campaign was also deemed essential in
414 enhancing trust and building sustainable relationships that would support future vaccine
415 uptake.

416 The feedback to the community leaders is very, very important, because we always
417 seek their permission, their help, their assistance, but we never give them feedback.
418 (Multilateral organisation, West Africa)

419
420 Respect, honesty, and meaningful discussion were stressed as principles crucial to building
421 trust:

422 There are many things that the communities need to understand. They may not be
423 intellectual ... but they are not stupid. They observe and ask relevant questions. So one
424 of the keys is to never hide the truth. Be frank and honest with them, because when they

425 trust you, they trust you forever. But when you lose [their] confidence, it's difficult.

426 (Multilateral organisation, West and Central Africa)

427 Communities want to actively participate in discussions about the need for, or benefit of, new
428 vaccines.[44] Providing community members with an opportunity to ask questions and query
429 points about the disease or vaccine is a crucial enabler for vaccination success. Participants
430 outlined how engaged community members often became champions for the campaign.

431

432 Participants affirmed that vaccines for well-known and feared diseases, like meningitis A and
433 yellow fever, generally had high community uptake, but social mobilisation was much more
434 difficult if diseases were not known or prioritised by communities. Generating demand for
435 vaccination where communities had other priorities outside the health sector was particularly
436 challenging.

437 [Community members] would say "What we need is a bridge, we need a road to be
438 repaired. ... When you have those things, bring the [vaccination] request." (National
439 health agency, West Africa)

440 Addressing this challenge, participants said, required detailed and focused communication
441 about the disease beyond simple vaccine uptake advocacy; working with communities to
442 ensure they had appropriate information to understand the disease, its severity, and the
443 burden on their communities.[44] Data on disease incidence is critical to these discussions.
444 Some participants highlighted concerns that limited COVID-19 case detection in African
445 countries would negatively impact community perceptions of disease burden and the need for
446 vaccination.

447

448 The current limited supply of COVID-19 vaccines presents a paradox for LMICs in terms of
449 community engagement and social mobilisation. While delayed vaccine delivery means

450 countries have more time to plan mobilisation activities, they lack the operational funding
451 required to design and deliver these activities. Further, generating demand in the face of
452 limited supply requires careful balancing of risks; some participants spoke of how they had
453 not yet employed previously used demand generation methods, such as SMS alerts, for
454 COVID-19 for fear of overwhelming their limited vaccine supply.

455 **7) Vaccine confidence**

456 *Responding to vaccine concerns*

457 Swift, transparent and trusted responses are needed to address vaccine concerns. Participants
458 stated that the longer a rumour circulates, the greater the risk to a vaccination campaign.
459 Influencers — political, religious, and traditional leaders or heads of social groups (e.g.,
460 women’s groups, youth groups, or sporting groups) — play an important role in
461 counteracting negative rumours. When rumours were spread by a prominent individual, such
462 as a religious leader, participants described using a similarly influential person to counter
463 those messages. Rumours spread by health professionals were especially difficult to address
464 and were best responded to by other health professionals. National Immunisation Technical
465 Advisory Groups can also play a role in fostering community confidence and dispelling
466 rumours by providing independent, evidence-based information on the disease and the
467 vaccination campaign.

468

469 Vaccine hesitancy in the COVID-19 response was perceived as particularly challenging
470 compared to previous campaigns. Participants attributed this to the global nature of the
471 pandemic and the propagation of rumours through social media.

472 The problem is that COVID-19 is too publicised, which is already a major obstacle to
473 acceptance. ... Unfortunately today, the world cannot control [the information]

474 because everyone has become an expert in COVID-19 vaccination or an expert in
475 COVID-19. (Multilateral organisation, West and Central Africa)

476 Several participants described how social media tracking and online rumour debunking were
477 incorporated into their COVID-19 response activities. Some countries have partnered with
478 social media and technology companies to provide accurate information through their
479 messaging forums. However, other participants described this as a weaker area of their
480 response, highlighting that further investment was needed to counter the proliferation of
481 misinformation and rumours. While participants described the unique challenge of rumours
482 circulating on social media, they also stressed the importance of continued face-to-face
483 interaction with communities to understand and respond to rumours in-person rather than
484 relying on information distributed online.

485
486 Participants noted that rumours around ‘vaccine testing’ were prevalent in both the EVD and
487 COVID-19 responses, but that community risk perceptions were different between the
488 campaigns.

489 [During the EVD response] there was lots of talk about being guinea pigs and
490 [people] would say, "yeah, we're guinea pigs", but a lot of people went, "actually, I'd
491 rather be a guinea pig and get vaccinated than get Ebola." ... Early on in the COVID-
492 19 outbreak [the population] said, "well, we're not willing to be guinea pigs for this
493 one because it's not our problem ... we are probably not going to die of COVID-19."
494 (NGO, Central Africa)

495 Participants spoke of how they explained the vaccine regulatory and approval processes to
496 communities, highlighting that COVID-19 vaccine trials had already been conducted in other
497 countries outside of Africa. However, changing community perceptions was considered

498 difficult due to misinformation and the absence of high disease incidence or severity that
499 might increase the prioritisation of COVID-19 vaccination within communities.

500 **DISCUSSION**

501 This research took place as the first doses of COVID-19 vaccines provided through COVAX
502 arrived in LMICs in Africa and South America. We reviewed the literature and interviewed
503 technical experts with extensive experience in epidemic vaccination campaigns to develop
504 recommendations for the rollout of COVID-19 vaccines in LMICs. Table 4 presents a set of
505 recommendations. Key recommendations include: prioritising time, funding and workforce
506 for community engagement; identifying effective training strategies to upskill vaccination
507 teams; streamlining response coordination and vaccination monitoring functions; and
508 exploring opportunities for health service integration.

509

510 **TABLE 4: Recommendations for the implementation of COVID-19 vaccines in LMICs,**
 511 **based on lessons from meningitis A, yellow fever and Ebola virus disease vaccination**
 512 **campaigns**

Recommendation	Domains
<ul style="list-style-type: none"> • Prioritise the availability of operational funds to support community engagement and social mobilisation well in advance of vaccination activities. 	<ul style="list-style-type: none"> • Planning and coordination • Community engagement and social mobilisation
<ul style="list-style-type: none"> • Develop a community engagement strategy that emphasises the principles of community involvement, co-development, and iterative adaptation. Vaccination teams should meet iteratively with community members, actively seek their questions and input on strategy development, and adapt vaccination strategies accordingly. 	<ul style="list-style-type: none"> • Community engagement and social mobilisation • Target groups and delivery strategies • Vaccine confidence
<ul style="list-style-type: none"> • Engage local, trusted health workers (including Community Health Workers) to support vaccination activities, ensuring a continued connection between communities and the vaccination campaign. 	<ul style="list-style-type: none"> • Vaccination teams • Community engagement and social mobilisation
<ul style="list-style-type: none"> • Develop rapid processes to recruit and manage an expanded vaccination workforce for the response. Care should be taken to balance response staffing requirements with the need to maintain existing services. 	<ul style="list-style-type: none"> • Vaccination teams
<ul style="list-style-type: none"> • Evaluate and refine training strategies to ensure vaccination teams are well equipped to conduct vaccination activities. Identify teams who are not able to access remote training and design suitable alternatives. 	<ul style="list-style-type: none"> • Vaccination teams
<ul style="list-style-type: none"> • Provide vaccination teams with clear guidance on the management of multi-dose vaccine vials, including which population groups should be offered leftover vaccine doses where the vial cannot be appropriately stored and used at a later time. 	<ul style="list-style-type: none"> • Vaccination teams • Logistics and supply
<ul style="list-style-type: none"> • Ensure national ownership, access and capacity to analyse vaccination campaign data, including the use of electronic data capture systems. 	<ul style="list-style-type: none"> • Vaccination monitoring and safety surveillance
<ul style="list-style-type: none"> • Work with technical leads across the outbreak response (e.g., surveillance, vaccination) to streamline the collection, aggregation and analysis of different indicators to support vaccination campaign monitoring. 	<ul style="list-style-type: none"> • Vaccination monitoring and safety surveillance
<ul style="list-style-type: none"> • Bring together response pillar leads and routine health programme leads to discuss opportunities to integrate health services during vaccination campaigns. Any integration of services should be well resourced, and well coordinated between services and with communities, to mitigate potential adverse impacts. 	<ul style="list-style-type: none"> • Target groups and delivery strategies

513

514 To date, gaps in operational funding for COVID-19 vaccination campaigns in LMICs have
515 prevented some vaccination teams from conducting crucial community engagement activities.
516 Mobilising communities in the face of limited COVID-19 vaccine supply is a difficult
517 balance. Nevertheless, while waiting for sufficient vaccines to be delivered, countries can
518 involve communities in the proposed rollout, listen to their concerns and devise solutions. It
519 is crucial that countries prioritise operational funds to support vaccination teams to
520 effectively conduct these preparatory activities.

521

522 There are several advantages to employing local health workers in vaccination campaigns.
523 Building on existing trust and rapport, local health workers can engage with communities,
524 discuss key information about the campaign, monitor vaccine acceptance levels and respond
525 to rumours as they arise. In order to employ local health workers that are not yet supporting
526 the COVID-19 response, countries must identify mechanisms to rapidly recruit and train
527 them. Evidence around effective training strategies for health workers in LMICs during
528 epidemics remains limited.[49, 50] While the ‘cascade’ or ‘training-of-trainers’ model is seen
529 as economical and rapidly scalable,[51] participants highlighted issues of quality as
530 information is transmitted to lower levels. Considering the key role health workers play in
531 mobilising communities and delivering vaccinations, countries must evaluate and refine
532 training strategies to effectively upskill their vaccination teams for COVID-19.

533

534 Co-administration of COVID-19 with other vaccines is not currently recommended by the
535 WHO Strategic Advisory Group of Experts on Immunization,[52] preventing potential
536 efficiency gains through integration. While integration can reduce time and cost burdens, it
537 introduces challenges around coordination, reporting, and staff capacity.[53] Further,
538 COVID-19 vaccine hesitancy may affect the uptake of other vaccines. The differentiation

539 between COVID-19 and other vaccines has perpetuated the belief that some vaccines are safe
540 while others are not. Without a concerted effort to change community perceptions around
541 COVID-19 vaccines, integrating other campaigns with COVID-19 vaccination is unlikely to
542 yield high uptake. Integrating other community-prioritised health services (e.g., antenatal
543 care) may be a more effective strategy. Careful planning with other health programmes and
544 communities is needed to identify and mitigate the potential effect of COVID-19 vaccine
545 hesitancy on other services. Considering the significant impact of COVID-19 on access to
546 routine health services in LMICs,[54, 55] the integration of services should be discussed and
547 pursued where appropriate.

548

549 Most COVID-19 vaccines currently under Emergency Use Listing (EUL) by WHO are
550 packaged in multi-dose vials.[21, 56] Multi-dose vaccine vials are widely used in LMICs as
551 they are cheaper and require less storage space.[57] However, health workers' reluctance to
552 open multi-dose vials for fear of vaccine wastage was identified in this research and has also
553 been reported for routine immunisation programmes in LMICs.[21, 56] The limited supply of
554 COVID-19 vaccines is likely to increase pressure on vaccination teams to minimise wastage,
555 which may be complicated by the strict prioritisation of target groups and instances where
556 sufficient eligible persons do not present for vaccination. To minimise wastage and reduce
557 the risk of loss-to-follow up, vaccination teams should be given clear guidelines for
558 administering the remaining doses in multi-dose vials to persons outside of priority groups.

559

560 Incident management systems provide direction and coordination across response activities,
561 including vaccination. However, the unprecedented scale and extended duration of the
562 COVID-19 pandemic has placed enormous pressure on key personnel within response
563 structures. The incident management system model is labour intensive.[58, 59] While there

564 has been a global recognition of frontline worker burnout, the effect of a protracted pandemic
565 on key personnel in countries' incident management systems should also be considered.[60]
566 Countries need to explore ways to streamline coordination processes and upskill additional
567 staff to fulfil IMS functions to ensure continuity in the response.

568

569 Due to the geographical distribution of the selected diseases and the distribution of the
570 research team's professional networks, this research draws primarily from vaccine
571 implementation experiences in LMICs in West, Central and East Africa. The findings may
572 not be generalisable to other geographic areas, which are likely to have their own set of
573 challenges in implementing vaccines. In addition, several identified technical experts could
574 not participate due to competing priorities, including the COVID-19 response and the EVD
575 outbreaks in the first half of 2021.

576

577 **CONCLUSION**

578 These recommendations rely on LMICs having sufficient vaccine supply to conduct
579 vaccination campaigns for COVID-19, which has not been the case in most settings. We
580 implore the global community to prioritise COVID-19 vaccine supply for LMICs. As vaccine
581 supplies increase, we encourage researchers to support countries in monitoring and
582 documenting their COVID-19 vaccination campaigns to understand real-time responses to
583 challenges and strengthen evidence around best practices during outbreak-related vaccination
584 campaigns in low-resource settings.

585

586 **Acknowledgements**

587 The authors would like to thank the technical experts who took time out of their busy
588 schedules in the midst of the COVID-19 pandemic and concurrent outbreaks to give
589 interviews and who generously shared their experiences, knowledge and insights to support
590 this research.

591

592 **Contributors**

593 All authors provided input into the conceptualisation of the study and its design. The
594 interviews and qualitative analysis were conducted by J.C and R.W with support from D.K.
595 The literature review was conducted by D.K with support from K.N and J.C. The manuscript
596 was prepared by J.C and D.K. All authors provided input into the manuscript and are
597 guarantors of the study.

598

599 **Funding**

600 This research was funded by UK Aid from the Department of Health and Social Care ([https://](https://www.gov.uk/government/collections/officialdevelopment-assistance-oda-2)
601 www.gov.uk/government/collections/officialdevelopment-assistance-oda-2, Grant No. IS-
602 RRT-1015-001) via the UK Public Health Rapid Support Team Research Programme. The
603 UK Public Health Rapid Support Team is funded by UK Aid from the Department of Health
604 and Social Care and is jointly run by Public Health England and the London School of
605 Hygiene & Tropical Medicine. The views expressed in this publication are those of the
606 author(s) and not necessarily those of the Department of Health and Social Care.

607

608 **Competing interests**

609 None declared.

610

611 **Patient consent**

612 Not required.

613

614 **Ethics approval**

615 The study was approved by the London School of Hygiene & Tropical Medicine Research
616 Ethics Committee (ref: 24044).

617

618 **Provenance and peer review**

619 Not commissioned; externally peer reviewed.

620

621 **Data sharing statement**

622 The qualitative data generated through this study are not suitable for sharing beyond that

623 contained within the manuscript in order to protect participants' anonymity. Further

624 information can be obtained from the corresponding author.

625 REFERENCES

- 626 1. Skegg D, Gluckman P, Boulton G, et al. Future scenarios for the COVID-19
627 pandemic. *The Lancet*. 2021;397(10276):777-8.
- 628 2. The Lancet Microbe. COVID-19 vaccines: the pandemic will not end overnight.
629 *Lancet Microbe*. 2021;2(1):e1-e.
- 630 3. So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross
631 sectional analysis. *BMJ*. 2020;371:m4750.
- 632 4. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19
633 vaccinations. *Nature Human Behaviour*. 2021.
- 634 5. World Health Organization. COVAX Announces additional deals to access promising
635 COVID-19 vaccine candidates; plans global rollout starting Q1 2021 2020. Available from:
636 [https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-](https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021)
637 [promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021](https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021). [Accessed on
638 25 January, 2021].
- 639 6. Guignard A, Praet N, Jusot V, et al. Introducing new vaccines in low- and middle-
640 income countries: challenges and approaches. *Expert Review of Vaccines*. 2019;18(2):119-31.
- 641 7. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of
642 COVID-19 vaccine in low-income countries. *npj Vaccines*. 2021;6(1):54.
- 643 8. World Health Organization. Global Ebola Vaccine Implementation Team
644 (GEVIT) Practical guidance on the use of Ebola vaccine in an outbreak response. 2016.
- 645 9. Ebola vaccine deployment aacEc. Ebola vaccine communication, community
646 engagement and compliance management (3C) gap analysis tool. 2019.
- 647 10. World Health Organization, UNICEF. Guidance on developing a national deployment
648 and vaccination plan for COVID-19 vaccines: Interim guidance. 2020.
- 649 11. Aguado MT, Jodar L, Granoff D, et al. From epidemic meningitis vaccines for Africa
650 to the meningitis vaccine project. *Clinical Infectious Diseases*. 2015;61(Supplement 5):S391-
651 S5.
- 652 12. Burchett HED, Mounier-Jack S, Torres-Rueda S, et al. The impact of introducing new
653 vaccines on the health system: Case studies from six low- and middle-income countries.
654 *Vaccine*. 2014;32(48):6505-12.
- 655 13. Marchetti E, Mazarin-Diop V, Chaumont J, et al. Conducting vaccine clinical trials in
656 sub-Saharan Africa: Operational challenges and lessons learned from the Meningitis Vaccine
657 Project. *Vaccine*. 2012;30(48):6859-63.
- 658 14. Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold
659 chain: Delivering Meningitis A vaccine in a controlled temperature chain during the mass
660 immunization campaign in Benin. *Vaccine*. 2014;32(13):1431-5.
- 661 15. Djingarey MH, Barry R, Bonkougou M, et al. Effectively introducing a new
662 meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. *Vaccine*.
663 2012;30:B40-B5.
- 664 16. Cibrelus L, Lingani C, Fernandez K, et al. Risk Assessment and Meningococcal A
665 Conjugate Vaccine Introduction in Africa: The District Prioritization Tool. *Clin Infect Dis*.
666 2015;61 Suppl 5(Suppl 5):S442-50.
- 667 17. Okwo-Bele JM, Cherian T. The expanded programme on immunization: A lasting
668 legacy of smallpox eradication. *Vaccine*. 2011;29(SUPPL. 4):D74-D9.
- 669 18. Tartof S, Cohn A, Tarbangdo F, et al. Identifying Optimal Vaccination Strategies for
670 Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt. *PLOS*
671 *ONE*. 2013;8(5):e63605.


- 672 19. Mbaeyi S, Sampo E, Dinanibe K, et al. Meningococcal carriage 7 years after
673 introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from
674 four cross-sectional carriage surveys. *The Lancet Infectious diseases*. 2020;20(12):1418-25.
- 675 20. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal
676 conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad:
677 A community study. *The Lancet*. 2014;383(9911):40-7.
- 678 21. Nkwenkeu SF, Jalloh MF, Walldorf JA, et al. Health workers' perceptions and
679 challenges in implementing meningococcal serogroup a conjugate vaccine in the routine
680 childhood immunization schedule in Burkina Faso. *BMC public health*. 2020;20(1):254.
- 681 22. Patel JC, Soeters HM, Diallo AO, et al. MenAfriNet: A Network Supporting Case-
682 Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa.
683 *Journal of Infectious Diseases*. 2019;220(Supplement 4):S148-S54.
- 684 23. Diomande FVK, Djingarey MH, Daugla DM, et al. Public health impact after the
685 introduction of PsA-TT: The first 4 years. *Clinical Infectious Diseases*. 2015;61(Supplement
686 5):S467-S72.
- 687 24. Berlier M, Barry R, Shadid J, et al. Communication Challenges During the
688 Development and Introduction of a New Meningococcal Vaccine in Africa. *Clinical
689 Infectious Diseases*. 2015;61(suppl_5):S451-S8.
- 690 25. Djingarey MH, Diomandé FV, Barry R, et al. Introduction and Rollout of a New
691 Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries,
692 2010-2014. *Clin Infect Dis*. 2015;61 Suppl 5(Suppl 5):S434-41.
- 693 26. Ughasoro MD, Esangbedo DO, Tagbo BN, et al. Acceptability and willingness-to-pay
694 for a hypothetical ebola virus vaccine in Nigeria. *PLoS Neglected Tropical Diseases*.
695 2015;9(6):e0003838.
- 696 27. Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola vaccine
697 experience for SARS-CoV-2 and other epidemic pathogens. *npj Vaccines*. 2020;5(1):51.
- 698 28. Jusu MO, Glauser G, Seward JF, et al. Rapid Establishment of a Cold Chain Capacity
699 of -60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra
700 Leone. *The Journal of infectious diseases*. 2018;217(suppl_1):S48-S55.
- 701 29. Samai M, Seward JF, Goldstein ST, et al. The Sierra Leone Trial to Introduce a
702 Vaccine Against Ebola: An Evaluation of rVSVDELTA-GP Vaccine Tolerability
703 and Safety during the West Africa Ebola Outbreak. *Journal of Infectious Diseases*.
704 2018;217(Supplement 1):S6-S15.
- 705 30. Dean NE, Gsell PS, Brookmeyer R, et al. Design of vaccine efficacy trials during
706 public health emergencies. *Science Translational Medicine*. 2019;11(499).
- 707 31. Hossmann S, Haynes AG, Spoerri A, et al. Data management of clinical trials during
708 an outbreak of Ebola virus disease. *Vaccine*. 2019;37(48):7183-9.
- 709 32. Grantz KH, Claudot P, Kambala M, et al. Factors influencing participation in an
710 Ebola vaccine trial among front-line workers in Guinea. *Vaccine*. 2019;37(48):7165-70.
- 711 33. Juan-Giner A, Tchaton M, Jemmy JP, et al. Safety of the rVSV ZEBOV vaccine
712 against Ebola Zaire among frontline workers in Guinea. *Vaccine*. 2019;37(48):7171-7.
- 713 34. Elemuwa C, Kutalek R, Ali M, et al. Global lessons from Nigerias ebolavirus control
714 strategy. *Expert Review of Vaccines*. 2015;14(11):1397-400.
- 715 35. Alenichev A, Peeters Grietens K, Gerrets R. Conceptions within misconceptions:
716 Pluralisms in an Ebola vaccine trial in West Africa. *Global Public Health*. 2020;15(1):13-21.
- 717 36. Folayan MO, Yakubu A, Haire B, et al. Ebola vaccine development plan: ethics,
718 concerns and proposed measures. *BMC Medical Ethics*. 2016;17(1):10.
- 719 37. Tomashek K, Challberg M, Nayak S, et al. Disease Resurgence, Production
720 Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a
721 Need for a New Yellow Fever Vaccine? *Vaccines*. 2019;7.

- 722 38. Chen LH, Hamer DH. Vaccination Challenges in Confronting the Resurgent Threat
723 From Yellow Fever. *Jama*. 2017;318(17):1651-2.
- 724 39. Vannice K, Wilder-Smith A, Hombach J. Fractional-Dose Yellow Fever Vaccination
725 — Advancing the Evidence Base. *New England Journal of Medicine*. 2018;379(7):603-5.
- 726 40. Barrett ADT. Yellow Fever in Angola and Beyond — The Problem of Vaccine
727 Supply and Demand. *New England Journal of Medicine*. 2016;375(4):301-3.
- 728 41. Possas C, Lourenco-de-Oliveira R, Tauil PL, et al. Yellow fever outbreak in Brazil:
729 the puzzle of rapid viral spread and challenges for immunisation. *Memorias do Instituto*
730 *Oswaldo Cruz*. 2018;113(10):e180278.
- 731 42. Martins RM, Maia MdLS, Farias RHG, et al. 17DD yellow fever vaccine. *Human*
732 *Vaccines & Immunotherapeutics*. 2013;9(4):879-88.
- 733 43. Flamand C, Bailly S, Fritzell C, et al. Vaccination coverage in the context of the
734 emerging Yellow Fever threat in French Guiana. *PLoS Neglected Tropical Diseases*.
735 2019;13(8):e0007661.
- 736 44. Legesse M, Endale A, Erku W, et al. Community knowledge, attitudes and practices
737 on Yellow fever in South Omo area, Southern Ethiopia. *PLoS neglected tropical diseases*.
738 2018;12(4):e0006409.
- 739 45. Nguyen T, Richardson S. Vaccine stockpile governance through partnership: The
740 International Coordination Group on Emergency vaccine provision and its impacts.
741 *International Journal of Infectious Diseases*. 2019;79(Supplement 1):132-3.
- 742 46. Yakum MN, Ateudjieu J, Walter EA, et al. Vaccine storage and cold chain monitoring
743 in the North West region of Cameroon: a cross sectional study. *BMC Research Notes*.
744 2015;8(1):145.
- 745 47. Sow C, Sanou C, Medah C, et al. Challenges of cold chain quality for routine EPI in
746 south-west Burkina-Faso: An assessment using automated temperature recording devices.
747 *Vaccine*. 2018;36(26):3747-55.
- 748 48. Kochhar S, Rath B, Seeber LD, et al. Introducing new vaccines in developing
749 countries. *Expert Rev Vaccines*. 2013;12(12):1465-78.
- 750 49. Nayahangan LJ, Konge L, Russell L, et al. Training and education of healthcare
751 workers during viral epidemics: a systematic review. *BMJ Open*. 2021;11(5):e044111.
- 752 50. Rowe AK, Rowe SY, Peters DH, et al. The effectiveness of training strategies to
753 improve healthcare provider practices in low-income and middle-income countries. *BMJ*
754 *Global Health*. 2021;6(1):e003229.
- 755 51. Mormina M, Pinder S. A conceptual framework for training of trainers (ToT)
756 interventions in global health. *Globalization and Health*. 2018;14(1):100.
- 757 52. World Health Organization. Interim recommendations for use of the Pfizer–BioNTech
758 COVID-19 vaccine, BNT162b2, under Emergency Use Listing. 2021.
- 759 53. Mounier-Jack S, Mayhew SH, Mays N. Integrated care: learning between high-
760 income, and low- and middle-income country health systems. *Health policy and planning*.
761 2017;32(suppl_4):iv6-iv12.
- 762 54. Robertson T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the
763 COVID-19 pandemic on maternal and child mortality in low-income and middle-income
764 countries: a modelling study. *The Lancet Global Health*. 2020;8(7):e901-e8.
- 765 55. Dixit SM, Sarr M, Gueye DM, et al. Addressing disruptions in childhood routine
766 immunisation services during the COVID-19 pandemic: perspectives from Nepal, Senegal
767 and Liberia. *BMJ Global Health*. 2021;6(7):e005031.
- 768 56. Krudwig K, Knittel B, Karim A, et al. The effects of switching from 10 to 5-dose
769 vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia.
770 *Vaccine*. 2020;38(37):5905-13.

- 771 57. Drain PK, Nelson CM, Lloyd JS. Single-dose versus multi-dose vaccine vials for
772 immunization programmes in developing countries. *Bulletin of the World Health*
773 *Organization*. 2003;81(10):726-31.
- 774 58. Richard B, Robert H, Paul C, et al. Adapting the Incident Management System for
775 response to health emergencies - early experience of WHO. *Weekly epidemiological record*.
776 2018;93(20):279-83.
- 777 59. Olu OO, Lamunu M, Chimbaru A, et al. Incident Management Systems Are Essential
778 for Effective Coordination of Large Disease Outbreaks: Perspectives from the Coordination
779 of the Ebola Outbreak Response in Sierra Leone. *Front Public Health*. 2016;4:254-.
- 780 60. Deng D, Naslund JA. Psychological Impact of COVID-19 Pandemic on Frontline
781 Health Workers in Low- and Middle-Income Countries. *Harv Public Health Rev (Camb)*.
782 2020;28.
- 783 61. World Health Organization. Vaccines and vaccination against yellow fever. WHO
784 position paper. 2013.
- 785 62. World Health Organization. Meningococcal vaccines: WHO position paper. 2011.
- 786 63. World Health Organization. WHO position paper, Meningococcal A conjugate
787 vaccine: Updated guidance, February 2015. *Weekly Epidemiological Record*. 2015;8(90):57-
788 68.
- 789 64. World Health Organization. WHO prequalifies Ebola vaccine, paving the way for its
790 use in high-risk countries 2019. Available from: <https://www.who.int/news/item/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries>. [Accessed
791 on 19 April, 2021].
- 792 65. Bache BE, Grobusch MP, Agnandji ST. Safety, immunogenicity and risk–benefit
793 analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across
794 regions. *Future Microbiology*. 2020;15(2):85-106.
- 795 66. World Health Organization. Ebola virus disease: Vaccines 2020. Available from:
796 <https://www.who.int/news-room/q-a-detail/ebola-vaccines>. [Accessed on 11 July, 2021].
- 797 67. World Health Organization. Community engagement: a health promotion guide for
798 universal health coverage in the hands of the people . 2020.
- 799 68. World Health Organization. Communication for behavioural impact: A toolkit for
800 behavioural and social communication in outbreak response.; 2012.
- 801

802

803



804

805 **FIGURE 1: Literature review flowchart**

806

807